Rodent Idiopathic Pulmonary Fibrosis (IPF) Models

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by excessive extracellular matrix deposition, alveolar destruction, and loss of lung function. HKeyBio offers three well-validated rodent IPF models: (1) BLM induced SD rat model, the most widely used model for IPF research, induced by intratracheal bleomycin instillation; (2) SiO2 induced C57BL/6 mouse model, representing occupational silica-induced lung fibrosis; and (3) SiOx induced SD rat model, a chronic fibrotic lung disease model caused by crystalline silica exposure. These models recapitulate key human IPF features including body weight loss, inflammatory cell infiltration in BALF, lung function decline, and progressive fibrotic pathology (Masson trichrome, HE, PSR staining). They provide robust platforms for preclinical efficacy testing of novel anti-fibrotic therapeutics.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Multiple etiologies – Chemical (BLM) and occupational (silica) induced models covering different IPF pathogenic mechanisms.

Comprehensive endpoints – Body weight, BALF cytology (inflammatory cells), lung function, histopathology (HE, Masson, PSR), pathology scoring.

Translational value – Ideal for testing anti-fibrotic drugs (nintedanib, pirfenidone), TGF-β inhibitors, and novel therapeutic candidates.

Species options – Rat and mouse models available to suit different experimental requirements.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

Representative data from our NHP Atopic Dermatitis (AD) Model：

BLM Induced C57BL/6 IPF Model

BLM Induced SD Rat IPF Model

SiO₂ Induced C57BL/6 IPF Model

SiO₂ Induced Rat IPF Model

Applications

• Efficacy testing of anti-fibrotic drugs (nintedanib, pirfenidone, TGF-β inhibitors, lysyl oxidase inhibitors)

• Target validation for fibrotic pathways (TGF-β, CTGF, PDGF)

• Biomarker discovery (collagen deposition markers, inflammatory mediators)

• Mechanism of action (MOA) studies

• IND-enabling pharmacology and toxicology studies

Model Specifications

Parameter	BLM Induced Rat IPF	SiO2 Induced Mouse IPF	SiOx Induced Rat IPF
Species/Strain	Sprague-Dawley rat	C57BL/6 mouse	Sprague-Dawley rat
Induction method	Intratracheal bleomycin (single dose)	Intratracheal SiO2 (single dose)	Intratracheal crystalline silica (SiOx)
Study duration	14–28 days	45 days	28–56 days
Key endpoints	Body weight, BALF cytology (total cells, differential), lung function, histopathology (HE, Masson), pathology scoring	Body weight, lung function, pathology score, histopathology (HE, Masson, PSR)	Body weight, BALF neutrophils, histopathology (HE, Masson, PSR)
Data package	Raw data, analysis reports, BALF cytology, histology slides (HE, Masson, PSR), lung function data, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What IPF models do you provide and what are their principles?

A1: We offer four mature rodent IPF models: BLM-induced and SiO2-induced models in C57BL/6 mice and SD rats. Bleomycin (BLM) triggers lung inflammation and fibrosis, while silicon dioxide (SiO₂) simulates fibrosis caused by silica exposure, both recapitulating the pathological features of idiopathic pulmonary fibrosis.

Q2: What evaluation indicators are used for these IPF models?

A2: Core assessments include body weight monitoring, lung function detection and bronchoalveolar lavage fluid (BALF) cell analysis. We also test hydroxyproline levels and perform pathological staining with HE, Masson and PSR for comprehensive fibrosis evaluation.

Q3: What are the modeling cycles of different IPF models?

A3: BLM-induced models: Single administration on Day 0, and animals are sacrificed on Day 28. SiO₂-induced mouse model: One-time dosing on Day 0, followed by sampling on Day 45. SiO₂-induced rat model: Dosing on Day 0 and sacrifice on Day 28.

Q4: What research scenarios are these IPF models suitable for?

A4: They are widely applied in preclinical efficacy screening, mechanism research and safety assessment of anti-fibrotic drugs, anti-inflammatory agents and targeted therapeutics for interstitial lung diseases and pulmonary fibrosis.

Q5: What are the advantages of your IPF animal models?

A5: These models feature stable molding effects and typical pathological changes highly consistent with human IPF. Multiple detection indicators support multi-dimensional data analysis. They are reliable and cost-effective for high-throughput preclinical drug development